11:21 AM EST, 11/07/2024 (MT Newswires) -- Clearside Biomedical ( CLSD ) said Thursday that its Asia-Pacific partner, Arctic Vision, entered into a commercial collaboration with Santen Pharmaceutical regarding the ARVN001 injection therapy for the treatment of uveitic macular edema and some other ophthalmic indications that are being developed.

Under the agreement, Arctic Vision has granted Santen rights to ARVN001 for the commercialization of the product candidate in China, excluding Taiwan, Hong Kong and Macau, Clearside said.

Clearside shares were up 2.3% in recent Thursday trading.

Price: 1.11, Change: +0.02, Percent Change: +2.31